Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

8.300 -0.500 (-5.68%)
Streaming Delayed Price Updated: 2:22 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
10 Analysts Assess Myriad Genetics: What You Need To Know
Via Benzinga
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
1 Small-Cap Stock on Our Watchlist and 2 to Avoid
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Analyst Expectations For Myriad Genetics's Future
Via Benzinga
Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts
Via Benzinga
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?
Myriad Genetics’s stock price has taken a beating over the past six months, shedding 65.1% of its value and falling to $9.99 per share. This might have investors contemplating their next move. 
Via StockStory
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50. 
Via Benzinga
Why Are Myriad Genetics (MYGN) Shares Soaring Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved outlook... 
Via StockStory
This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad reaffirms guidance and names a new CEO. 
Via Benzinga
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
From Myriad Genetics, Inc.
Via GlobeNewswire
Why Myriad Genetics (MYGN) Shares Are Plunging Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025... 
Via StockStory
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. 
Via StockStory
Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The company’s full-year revenue... 
Via StockStory
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Senior Leadership Transition
Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
From Myriad Genetics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 24, 2025
Via Benzinga
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know. 
Via StockStory
Myriad Genetics Included in Forbes America’s Best Employers 2025 List
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
Management will participate in three upcoming investor healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
3 Reasons to Sell MYGN and 1 Stock to Buy Instead
Myriad Genetics’s stock price has taken a beating over the past six months, shedding 47.8% of its value and falling to $14.75 per share. This might have investors contemplating their next move. 
Via StockStory
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.